Clinical Trial Search

Primary: Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28) — -1.56 scores on a scale

Primary: The Prevalence of Incomplete Excision of Dysplasia at the Endocervical Excision Margin as Recognized Histologically. — 28; 39 participants

Primary: Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count — 2.05 discrepancies/200 dose cycles

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60; 31 Patients

Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90 — 41.77; 40.92; -16.88; -15.97 score on a scale

Primary: The Primary Effectiveness Endpoint is the Successful Navigation and EGM Recording of Each Pre-specified Pulmonary Vein Per Procedure Between Both the Control and the…

Primary: Minutes of Moderate or Vigorous Physical Activity Per Week After 12-months — 246; 156 minutes per week moderate-to-vigorous PA

Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 14; 10 number of participants with…

Primary: Percentage of Subjects on Lacosamide (LCM) Monotherapy at Any Time Between Visit 1 and End of Study — 292 Participants

Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match) — 17.9; 18.0 percentage of participants — p=0.996

Primary: Percent Change in Fasting Triglycerides From Baseline to 12 Weeks — 45.6; 3.7; -13.9 percent change — p=0.0538

Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 11; 20 participants — p=0.789

Primary: Measure: Pain On Movement (POM) — 42.9; 42.1 units on a scale

Primary: 24-hour Mortality — 43; 58 participants — p=0.12

Primary: Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study — 6.304; 5.921; 4.087; 3.675 mMol/L